Validation of the KELIM score as a predictor of response to neoadjuvant treatment in patients with advanced high grade serous ovarian cancer.

导出原文传递

翻译打印收藏纠错

作者： Sabrina,Piedimonte ^[1] ; Rachel,Kim ^[1] ; Marcus Q,Bernardini ^[2] ; Eshetu G,Atenafu ^[3] ; Mitchell,Clark ^[4] ; Stephanie,Lheureux ^[5] ; Taymaa,May ^[6]

作者单位： Division of Gynecologic Oncology, University of Toronto, Toronto, Ontario, Canada. ^[1] Division of Gynecologic Oncology, University of Toronto, Toronto, Ontario, Canada; Division of Gynecologic Oncology, Department of Surgical Oncology, Princess Margaret Cancer Center, Toronto, Ontario, Canada. ^[2] Division of Biostatistics and Epidemiology, University Health Network, Toronto, Ontario, Canada. ^[3] Smilow Cancer Center, Yale University, CT, USA. ^[4] Division of Medical Oncology, Princess Margaret Cancer Center, Toronto, Ontario, Canada. ^[5] Division of Gynecologic Oncology, University of Toronto, Toronto, Ontario, Canada; Division of Gynecologic Oncology, Department of Surgical Oncology, Princess Margaret Cancer Center, Toronto, Ontario, Canada. Electronic address: Taymaa.May@uhn.ca. ^[6]

关键词 CA-125 KELIM score Neoadjuvant chemotherapy Ovarian cancer Survival

主题词人类(Humans);女(雌)性(Female);卵巢肿瘤(Ovarian Neoplasms);肿瘤辅助疗法(Neoadjuvant Therapy);回顾性研究(Retrospective Studies)

DOI 10.1016/j.ygyno.2022.10.014

PMID 37191644

发布时间 2023-05-22

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交